Natural active molecules are key sources of modern innovative drugs. Particularly, a great amount of natural active molecules have been reported to possess promising therapeutic effects on inflammatory diseases, inclu...Natural active molecules are key sources of modern innovative drugs. Particularly, a great amount of natural active molecules have been reported to possess promising therapeutic effects on inflammatory diseases, including asthma, rheumatoid arthritis, hepatitis, enteritis, metabolic disorders and neurodegenerative diseases. However, these natural active molecules with various molecular structures usually exert anti-inflammatory effects through diversiform pharmacological mechanisms, which is necessary to be summarized systematically. In this review, we introduced the current major anti-inflammatory natural active molecules based on their chemical structures, and discussed their pharmacological mechanisms including anti-inflammatory molecular signaling pathways and potential target proteins, which providing a referential significance on the development of novel anti-inflammatory drugs, and also revealing new therapeutic strategies for inflammatory diseases.展开更多
Within the public health sector of Hong Kong(China),there is a consensus around the important role of traditional Chinese medicines.For Hong Kong(China)to play a bridging role to bring Chinese medicines to the global ...Within the public health sector of Hong Kong(China),there is a consensus around the important role of traditional Chinese medicines.For Hong Kong(China)to play a bridging role to bring Chinese medicines to the global market requires a concerted effort from the government,academic institutes and industries.The release of the final version of the European Medicines Agencies guidance document,which details the acceptance of minimum requirements to nonclinical package in bibliographical applications,grants the opportunity for well-established and traditional herbal medicines to demonstrate an‘acceptable safe’status for registration in the European Union.It is anticipated that this minimum nonclinical package can be applied to demonstrate the safe use of many traditional Chinese medicines regardless of their eligibility to be registered under the simplified procedure within the European Union.This paper conceptualizes an integration of a simplified evaluation route for eligible proprietary Chinese medicines(pCm)with long history of use into the existing drug regulatory framework in Hong Kong(China).Such integration utilizing the minimum nonclinical package,based on bibliographical data or expert report,as proof of evidence to demonstrate safety for pCm with long history of use requires less demand in scientific resources.With Hong Kong(China)conducting‘first hand’review for eligible pCm,it provides an option for overseas and local pharmaceutical companies to register their products in Hong Kong(China)without the need to rely on issuance of Certificate of Pharmaceutical Product from other countries.This could bring eligible pCm with long history of use to reach international risk-based standard and to be marketed globally as‘medicines’to reach their full therapeutic potential.An important process to positioning Hong Kong(China)to compete with other countries in promoting importation and exportation of pCm to better serve the global health.展开更多
Autoimmune diseases such as rheumatoid arthritis (RA) cause significant morbidity and loss of productivity. Many potent conventionally used drugs are available for these diseases, but their prolonged use is accompanie...Autoimmune diseases such as rheumatoid arthritis (RA) cause significant morbidity and loss of productivity. Many potent conventionally used drugs are available for these diseases, but their prolonged use is accompanied by severe adverse effects besides a high cost.Therefore, there is an unmet need for effective but less expensive medications for RA and other autoimmune diseases. Natural plant products belonging to the traditional systems of medicine, such as the traditional Chinese medicine and Indian Ayurvedic medicine, offer a vast and promising resource in this regard. However, herbal medicinal products are often poorly characterized for their composition as well as mechanisms of action. We review here the results of our systematically performed studies aimed at defining the anti-arthritic activity of three herbal extracts, namely, modified Huo-luo-xiao-ling dan (HLXL), Celastrus aculeatus Merr., and polyphenolic fraction of green tea (Camellia sinensis), as well as a purifiedcompound Celastrol, a bioactive component of Celastrus. Specifically, we examined the effects of these herbal products on the immunological, biochemical and molecular biological effector pathways in autoimmune arthritis. We have also reviewed here related studies on these herbal products by other investigators. Taken together, we suggest further testing of these herbal products in RA patients.展开更多
介绍了多变量统计过程控制(multivariate statistical process control,MSPC)的基本概念和有关背景。描述了MSPC实施的基本流程以及常用统计量与控制图。强调了MSPC在药品生产过程中的重要作用,特别是中药领域,为药品生产过程质量控制...介绍了多变量统计过程控制(multivariate statistical process control,MSPC)的基本概念和有关背景。描述了MSPC实施的基本流程以及常用统计量与控制图。强调了MSPC在药品生产过程中的重要作用,特别是中药领域,为药品生产过程质量控制方法的选择提供参考。总结了MSPC的优势和不足,并展望了MSPC在药品生产和质量控制方面的发展趋势。展开更多
The outbreak and spread of coronavirus disease 2019(COVID-19)highlighted the importance and urgency of the research and development of therapeutic drugs.Very early into the COVID-19 pandemic,China has begun developing...The outbreak and spread of coronavirus disease 2019(COVID-19)highlighted the importance and urgency of the research and development of therapeutic drugs.Very early into the COVID-19 pandemic,China has begun developing drugs,with some notable progress.Herein,we summarizes the anti-COVID-19 drugs and promising drug candidates originally developed and researched in China.Furthermore,we discussed the developmental prospects,mechanisms of action,and advantages and disadvantages of the anti-COVID-19 drugs in development,with the aim to contribute to the rational use of drugs in COVID-19 treatment and more effective development of new drugs against severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)and the variants.Neutralizing antibody is an effective approach to overcome COVID-19.However,drug resistance induced by rapid virus mutation will likely to challenge neutralizing antibodies.Taking into account current epidemic trends,small molecule drugs have a crucial role in fighting COVID-19 due to their significant advantage of convenient administration and affordable and broad-spectrum.Traditional Chinese medicines,including natural products and traditional Chinese medicine prescriptions,contribute to the treatment of COVID-19 due to their unique mechanism of action.Currently,the research and development of Chinese anti-COVID-19 drugs have led to some promising achievements,thus prompting us to expect even more rapidly available solutions.展开更多
基金This work was supported by grants from the National Key Technology R & D Program “New Drug Innovation” of China (No. 2017ZX09101003-008-003)the Natural Science Foundation of China (No. 81773932).
文摘Natural active molecules are key sources of modern innovative drugs. Particularly, a great amount of natural active molecules have been reported to possess promising therapeutic effects on inflammatory diseases, including asthma, rheumatoid arthritis, hepatitis, enteritis, metabolic disorders and neurodegenerative diseases. However, these natural active molecules with various molecular structures usually exert anti-inflammatory effects through diversiform pharmacological mechanisms, which is necessary to be summarized systematically. In this review, we introduced the current major anti-inflammatory natural active molecules based on their chemical structures, and discussed their pharmacological mechanisms including anti-inflammatory molecular signaling pathways and potential target proteins, which providing a referential significance on the development of novel anti-inflammatory drugs, and also revealing new therapeutic strategies for inflammatory diseases.
文摘Within the public health sector of Hong Kong(China),there is a consensus around the important role of traditional Chinese medicines.For Hong Kong(China)to play a bridging role to bring Chinese medicines to the global market requires a concerted effort from the government,academic institutes and industries.The release of the final version of the European Medicines Agencies guidance document,which details the acceptance of minimum requirements to nonclinical package in bibliographical applications,grants the opportunity for well-established and traditional herbal medicines to demonstrate an‘acceptable safe’status for registration in the European Union.It is anticipated that this minimum nonclinical package can be applied to demonstrate the safe use of many traditional Chinese medicines regardless of their eligibility to be registered under the simplified procedure within the European Union.This paper conceptualizes an integration of a simplified evaluation route for eligible proprietary Chinese medicines(pCm)with long history of use into the existing drug regulatory framework in Hong Kong(China).Such integration utilizing the minimum nonclinical package,based on bibliographical data or expert report,as proof of evidence to demonstrate safety for pCm with long history of use requires less demand in scientific resources.With Hong Kong(China)conducting‘first hand’review for eligible pCm,it provides an option for overseas and local pharmaceutical companies to register their products in Hong Kong(China)without the need to rely on issuance of Certificate of Pharmaceutical Product from other countries.This could bring eligible pCm with long history of use to reach international risk-based standard and to be marketed globally as‘medicines’to reach their full therapeutic potential.An important process to positioning Hong Kong(China)to compete with other countries in promoting importation and exportation of pCm to better serve the global health.
文摘Autoimmune diseases such as rheumatoid arthritis (RA) cause significant morbidity and loss of productivity. Many potent conventionally used drugs are available for these diseases, but their prolonged use is accompanied by severe adverse effects besides a high cost.Therefore, there is an unmet need for effective but less expensive medications for RA and other autoimmune diseases. Natural plant products belonging to the traditional systems of medicine, such as the traditional Chinese medicine and Indian Ayurvedic medicine, offer a vast and promising resource in this regard. However, herbal medicinal products are often poorly characterized for their composition as well as mechanisms of action. We review here the results of our systematically performed studies aimed at defining the anti-arthritic activity of three herbal extracts, namely, modified Huo-luo-xiao-ling dan (HLXL), Celastrus aculeatus Merr., and polyphenolic fraction of green tea (Camellia sinensis), as well as a purifiedcompound Celastrol, a bioactive component of Celastrus. Specifically, we examined the effects of these herbal products on the immunological, biochemical and molecular biological effector pathways in autoimmune arthritis. We have also reviewed here related studies on these herbal products by other investigators. Taken together, we suggest further testing of these herbal products in RA patients.
文摘介绍了多变量统计过程控制(multivariate statistical process control,MSPC)的基本概念和有关背景。描述了MSPC实施的基本流程以及常用统计量与控制图。强调了MSPC在药品生产过程中的重要作用,特别是中药领域,为药品生产过程质量控制方法的选择提供参考。总结了MSPC的优势和不足,并展望了MSPC在药品生产和质量控制方面的发展趋势。
基金This study was supported by National Natural Science Foundation of China(NSFC,Grant No.81803614).
文摘The outbreak and spread of coronavirus disease 2019(COVID-19)highlighted the importance and urgency of the research and development of therapeutic drugs.Very early into the COVID-19 pandemic,China has begun developing drugs,with some notable progress.Herein,we summarizes the anti-COVID-19 drugs and promising drug candidates originally developed and researched in China.Furthermore,we discussed the developmental prospects,mechanisms of action,and advantages and disadvantages of the anti-COVID-19 drugs in development,with the aim to contribute to the rational use of drugs in COVID-19 treatment and more effective development of new drugs against severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)and the variants.Neutralizing antibody is an effective approach to overcome COVID-19.However,drug resistance induced by rapid virus mutation will likely to challenge neutralizing antibodies.Taking into account current epidemic trends,small molecule drugs have a crucial role in fighting COVID-19 due to their significant advantage of convenient administration and affordable and broad-spectrum.Traditional Chinese medicines,including natural products and traditional Chinese medicine prescriptions,contribute to the treatment of COVID-19 due to their unique mechanism of action.Currently,the research and development of Chinese anti-COVID-19 drugs have led to some promising achievements,thus prompting us to expect even more rapidly available solutions.
